Promising pipeline CD47 antigen inhibitors such as IMC-002, MP 0621, HCB-101, PT-217, HX 009, Maplirpacept, IBI 322, ALX-148, HMPL-A83 and others are under different phases of CD47 antigen ...

Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug in solid tumours ...